We would love to hear your thoughts about our site and services, please take our survey here.
From Bio-Techne
“ “Customers prefer Jess because it has higher throughput than western blot. Furthermore, Jess is faster and more reliable in terms of quantification and allows us to use low sample volumes, for example, difficult-to-obtain samples such as derived neurons of iPSC.”
Looking good for CIZ1b biomarker.
Neil thanks for taking the time to reply. Appreciated. Need to do some more digging
Tech - I’m not entirely convinced yet regarding the type and progress of the patent application. The fast track 12 months timescale suggests end of March if you take it from the application date but will be August at least if it’s from publication.
If CIZ haven’t paid for the faster application process (given how tight they are with RNS’s) then it’s a longer process.
My own view is CIZ may want to wait until the patent is granted before commercial launch.
It’s whether they actually have the product ready for launch that’s the main question.
Seems the granting of CIZ’s patent could be the catalyst for news flow here.
Applied for 23/3/23 published August 2023. If it’s 12 months from application then end of March onwards could be a last chance to get sub 3p here.
If it takes the longer patent timeline 22-36 months then it’s going to be a long time sitting on hands.
Neil thanks. Re read your post. Is the patent application definitely Priority. If so I believe 6-12 months is suggested application to grant for priority applications.
That would mean grant of patent end of March if the 12 months is from 23/3/23 filing date?
If it’s not priority then 22 months earliest.
Granting of the patent would be timely before commercial launch and Options/Warrant expiry dates.
Stupid question but can the patent be issued without a commercially available LDT or will it coincide with confirmation the LDT test has received regulatory approvals for commercialisation?
Couple of points jump out. Are they just catch all paragraphs inserted into the Patrnt filing or is there more to it?
“ The present invention also provides an anticancer drug for use in treating cancer wherein the subject has been identified as having cancer by the method of the invention.
The present invention further provides an anticancer lung cancer drug for use in treating lung cancer wherein the subject has been identified as having lung cancer by the method of the invention.”
“ The Company’s key business strategies for long-term growth and profitability continue to be geographic expansion, core product innovation, acquisitions and talent retention and development.”
“ Consistent with the prior year, we have operated with two segments – our Protein Sciences segment and our Diagnostics and Genomics segment – during the second quarter of fiscal 2024. Our Protein Sciences segment is a leading developer and manufacturer of high-quality purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. Our Diagnostics and Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx®Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.”
“ A key component of the Company's strategy is to augment internal growth at existing businesses with complementary acquisitions.”
CIZ with just the commercial agreement in China and Heads of terms with CorePath, currently, you have to say CIZ is nicely packaged for acquisition and the founders nicely placed to “retire”.
8 cent dividend every quarter can’t be bad or do you think it’s just because of CIZ ?
MINNEAPOLIS, Feb. 1, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2023. The quarterly dividend will be payable February 26, 2024, to all common shareholders of record on February 12, 2024. Future cash dividends will be considered by the Board of Directors on a quarterly basis.